VIRGINIA RETIREMENT SYSTEMS ET Al Has $1.71 Million Stake in Teladoc Health, Inc. $TDOC

VIRGINIA RETIREMENT SYSTEMS ET Al grew its holdings in Teladoc Health, Inc. (NYSE:TDOC) by 62.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 243,525 shares of the health services provider’s stock after purchasing an additional 93,450 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Teladoc Health were worth $1,705,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. IFP Advisors Inc grew its stake in shares of Teladoc Health by 412.1% in the 3rd quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after buying an additional 3,210 shares in the last quarter. Aster Capital Management DIFC Ltd boosted its position in shares of Teladoc Health by 101.1% in the third quarter. Aster Capital Management DIFC Ltd now owns 4,823 shares of the health services provider’s stock valued at $37,000 after acquiring an additional 2,425 shares during the period. International Assets Investment Management LLC bought a new stake in shares of Teladoc Health in the fourth quarter valued at approximately $45,000. Bayforest Capital Ltd bought a new stake in shares of Teladoc Health in the third quarter valued at approximately $58,000. Finally, KBC Group NV boosted its position in shares of Teladoc Health by 88.3% in the fourth quarter. KBC Group NV now owns 9,632 shares of the health services provider’s stock valued at $67,000 after acquiring an additional 4,516 shares during the period. Institutional investors own 76.82% of the company’s stock.

Teladoc Health Stock Performance

Teladoc Health stock opened at $6.37 on Friday. Teladoc Health, Inc. has a 52-week low of $4.40 and a 52-week high of $9.77. The firm has a market capitalization of $1.15 billion, a P/E ratio of -6.56 and a beta of 2.08. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.80 and a quick ratio of 2.72. The stock has a fifty day moving average price of $5.73 and a two-hundred day moving average price of $6.32.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. The business had revenue of $613.85 million during the quarter, compared to analyst estimates of $611.04 million. During the same quarter last year, the business posted ($0.53) earnings per share. The business’s quarterly revenue was down 2.5% compared to the same quarter last year. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. As a group, analysts anticipate that Teladoc Health, Inc. will post -0.92 EPS for the current fiscal year.

Insider Transactions at Teladoc Health

In related news, CEO Charles Divita III sold 27,731 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $5.49, for a total value of $152,243.19. Following the transaction, the chief executive officer owned 364,784 shares in the company, valued at $2,002,664.16. This trade represents a 7.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.70% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Bank of America raised Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Thursday, February 26th. Oppenheimer cut their target price on Teladoc Health from $12.00 to $7.00 and set an “outperform” rating for the company in a research note on Tuesday, March 3rd. BMO Capital Markets cut their target price on Teladoc Health from $8.00 to $5.00 and set a “market perform” rating for the company in a research note on Thursday, February 26th. Barclays cut their target price on Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating for the company in a research note on Thursday, March 26th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Teladoc Health in a research note on Friday, March 27th. Five investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Teladoc Health presently has a consensus rating of “Hold” and an average target price of $7.53.

Teladoc Health News Summary

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Zacks Research raised estimates for several near- and medium-term periods, including Q1 2028, Q2 2027, Q1 2027, Q3 2026, Q2 2026 and FY2026, suggesting slightly better expected profitability than before. BetterHelp Joins Patient Safety Organization to Advance Quality and Safety Practices in Virtual Mental Health Care
• Neutral Sentiment: BetterHelp, Teladoc’s online therapy business, joined a Patient Safety Organization to improve quality and safety in virtual mental health care, which is more of a long-term operational/brand-positive development than an immediate financial catalyst. BetterHelp Joins Patient Safety Organization to Advance Quality and Safety Practices in Virtual Mental Health Care
• Negative Sentiment: Analysts also cut estimates for some future periods, including Q4 2026, Q3 2027, Q4 2027, FY2027 and FY2028, reinforcing concerns that Teladoc may still face earnings pressure.
• Negative Sentiment: The broader context remains weak: Teladoc recently posted a quarterly EPS miss and management’s guidance still points to losses, which can weigh on investor sentiment toward TDOC.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.